What is Intercept Pharmaceuticals' stock symbol?
Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."
Where is Intercept Pharmaceuticals' stock going? Where will Intercept Pharmaceuticals' stock price be in 2017?
17 brokerages have issued 12-month price targets for Intercept Pharmaceuticals' stock. Their forecasts range from $60.00 to $350.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $187.12 in the next year.
When will Intercept Pharmaceuticals announce their earnings?
Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
What are analysts saying about Intercept Pharmaceuticals stock?
Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
Needham & Company LLC analysts commented, "Intercept reported 4Q16 financial results today. Ocaliva sales were $13.4M, compared to our $9.0M and consensus $7.8M est. Mgmt cited better than expected gross:net. No sales guidance was issued, as expected, although mgmt indicated 1Q17 sales will only be modestly above 4Q16, w/ expectations for gross:net to worsen. As a reminder, drug was launched in Jun 2016 for treatment of PBC. Ocaliva launch is progressing well, but we believe this is already factored in stock. Mgmt recently negotiated changes to Phase 3 REGENERATE NASH trial design, allowing for smaller pt population. We expect a favorable outcome, but note results will still not be available until 1H19." (2/23/2017)
Cantor Fitzgerald analysts commented, "With concerns in Nov. 2016 to achieve REGENERATE interim enrollment by 1H17, Intercept amended protocols and now expects completion by mid-2017." (2/13/2017)
- Wedbush analysts commented, "Intercept announced two protocol amendments to the Phase 3 REGENERATE trial including updating the definition of NASH resolution to the newer objective definition and only requiring statistical significance of one of the two components (NASH resolution without worsening of fibrosis and improvement in fibrosis without worsening of NASH) making up the co-primary endpoint in the ITT patient population. The previous definition of NASH resolution was the absence (score of zero) of at least one of the three components of NASH (steatosis, ballooning, or inflammation; Gastroenterology 2016; 150:1147-59) to the absence of ballooning (score to zero from 0-2) and residual (score of 1) or no (score of 0) inflammation (from 0-3). The new objective definition of NASH resolution is in-line with Genfit's ongoing Phase 3 NASH trial (March 10, 2016 press release)." (2/8/2017)
According to Zacks Investment Research, "Intercept received a major boost with the approval of its lead drug, Ocaliva, in combination with ursodeoxycholic acid (UDCA), for the treatment of primary biliary cholangitis (PBC) in both the U.S. and the EU. Successful commercialization of the drug will significantly boost the company’s revenues, going forward. The PBC market holds strong potential. We are also encouraged by Intercept’s efforts to develop the drug in additional indications. Loss estimates have narrowed lately ahead of the company’s Q4 earnings release. The company has a positive record of earnings surprises in the recent quarters. Moreover, the company’s share price outperformed the industry in the last twelve months. However, expenses will continue to rise in the coming quarters as the company prepares for a potential launch of Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline." (1/19/2017)
FBR & Co analysts commented, "At the annual meeting of the AASLD (American Association for the Study of Liver Diseases) held in Boston, Massachusetts, November 11–15, Intercept Pharmaceuticals and its collaborators presented results from three post-hoc analyses of the completed POISE Phase III trial with Ocaliva in patients with primary biliary cholangitis (PBC). In parsing through the analyses presented, we came away with a more definitive picture of the wealth of data generated by POISE, which is the pivotal trial that gained Ocaliva FDA approval in May 2016. Importantly, the analyses provide data that may be added to the compendium of information that supports Ocaliva’s nascent potential in PBC." (11/18/2016)
Who owns Intercept Pharmaceuticals stock?
Intercept Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Orbimed Advisors LLC (4.51%), State Street Corp (3.03%), Marshall Wace LLP (0.41%), White Square Capital LLP (0.26%) and National Planning Corp (0.21%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, David Shapiro, Jonathan Silverstein, Klaus R Dr Veitinger, Lisa Bright, Luciano Adorini, Mark Pruzanski, Nicole Williams, Orbimed Advisors Llc and Rachel Mcminn.
Who sold Intercept Pharmaceuticals stock? Who is selling Intercept Pharmaceuticals stock?
Intercept Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Credit Agricole S A, Metropolitan Life Insurance Co. NY, Van ECK Associates Corp, First Republic Investment Management Inc., Federated Investors Inc. PA and Guggenheim Capital LLC. Company insiders that have sold Intercept Pharmaceuticals stock in the last year include Barbara Gayle Duncan, David Shapiro, Lisa Bright, Mark Pruzanski and Rachel Mcminn.
Who bought Intercept Pharmaceuticals stock? Who is buying Intercept Pharmaceuticals stock?
Intercept Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Marshall Wace LLP, White Square Capital LLP, ING Groep NV, FMR LLC, A.R.T. Advisors LLC, Numeric Investors LLC and State Board of Administration of Florida Retirement System.
How do I buy Intercept Pharmaceuticals stock?
Shares of Intercept Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Intercept Pharmaceuticals stock cost?
One share of Intercept Pharmaceuticals stock can currently be purchased for approximately $115.93.